Scopolamine is a parasympatholytic drug that can modulate uterine contractile activity. Based on the hypothesis that deficiency in uterine contractility is a cause of Repeat Breeder (RB) syndrome in cows, this study aimed to evaluate the efficacy of scopolamine administration in RB cows, on the day of heat, in increasing conception rates. Forty RB cows were randomly divided into treated group [T; 20 cows treated with scopolamine butylbromide 40 mg/100 kg of body weight (BW) by the intramuscular (IM) route after clinical confirmation of heat (T0)] and the control group [C; 20 cows treated with 2 mL/100 kg of BW of saline solution, IM, at T0]. Twelve hours later (T1), all of the cows were artificially inseminated (AI). Blood plasma-progesterone (P4), hydroxyproline, and prostaglandin F2α metabolite (PGFM), concentrations were assessed at T0 and T1. Additionally, the uterine tone was evaluated by transrectal palpation. Conception rates were recorded. Drug administration increased the conception rates in group T to 80% unlike group C (25%) (P < 0.0001). Higher PGFM concentration levels were registered in the treated group than in the control group. The higher PGF2α secretion in pregnant cows of the T group may have reduced the P4 levels, making conception possible. Scopolamine administration at the time of heat can improve uterine contractility. This makes it more suitable for promoting conception in RB cows, where hormonal alterations and contractile and biochemical deficits are responsible for the syndrome.
Scopolamine administration in repeat breeder cows on the day of heat
Rizzo A.;Lillo E.;Ceci E.;Maggiolino A.;Cicirelli V.;Sciorsci R. L.
2023-01-01
Abstract
Scopolamine is a parasympatholytic drug that can modulate uterine contractile activity. Based on the hypothesis that deficiency in uterine contractility is a cause of Repeat Breeder (RB) syndrome in cows, this study aimed to evaluate the efficacy of scopolamine administration in RB cows, on the day of heat, in increasing conception rates. Forty RB cows were randomly divided into treated group [T; 20 cows treated with scopolamine butylbromide 40 mg/100 kg of body weight (BW) by the intramuscular (IM) route after clinical confirmation of heat (T0)] and the control group [C; 20 cows treated with 2 mL/100 kg of BW of saline solution, IM, at T0]. Twelve hours later (T1), all of the cows were artificially inseminated (AI). Blood plasma-progesterone (P4), hydroxyproline, and prostaglandin F2α metabolite (PGFM), concentrations were assessed at T0 and T1. Additionally, the uterine tone was evaluated by transrectal palpation. Conception rates were recorded. Drug administration increased the conception rates in group T to 80% unlike group C (25%) (P < 0.0001). Higher PGFM concentration levels were registered in the treated group than in the control group. The higher PGF2α secretion in pregnant cows of the T group may have reduced the P4 levels, making conception possible. Scopolamine administration at the time of heat can improve uterine contractility. This makes it more suitable for promoting conception in RB cows, where hormonal alterations and contractile and biochemical deficits are responsible for the syndrome.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.